MX2022007957A - Proteinas de union a o anticuerpos contra cd163. - Google Patents

Proteinas de union a o anticuerpos contra cd163.

Info

Publication number
MX2022007957A
MX2022007957A MX2022007957A MX2022007957A MX2022007957A MX 2022007957 A MX2022007957 A MX 2022007957A MX 2022007957 A MX2022007957 A MX 2022007957A MX 2022007957 A MX2022007957 A MX 2022007957A MX 2022007957 A MX2022007957 A MX 2022007957A
Authority
MX
Mexico
Prior art keywords
porcine
binds
amino acid
antigen binding
binding domain
Prior art date
Application number
MX2022007957A
Other languages
English (en)
Spanish (es)
Inventor
Charles Owen
Hafid Abdelaali Benchaoui
Christine Tait-Burkard
Original Assignee
Eco Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eco Animal Health Ltd filed Critical Eco Animal Health Ltd
Publication of MX2022007957A publication Critical patent/MX2022007957A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022007957A 2019-12-24 2020-12-24 Proteinas de union a o anticuerpos contra cd163. MX2022007957A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1919294.7A GB201919294D0 (en) 2019-12-24 2019-12-24 Antibodies or binding proteins
PCT/GB2020/053370 WO2021130502A1 (en) 2019-12-24 2020-12-24 Cd163 antibodies or binding proteins

Publications (1)

Publication Number Publication Date
MX2022007957A true MX2022007957A (es) 2022-10-07

Family

ID=69322779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007957A MX2022007957A (es) 2019-12-24 2020-12-24 Proteinas de union a o anticuerpos contra cd163.

Country Status (13)

Country Link
US (1) US20230203185A1 (enExample)
EP (1) EP4081542A1 (enExample)
JP (1) JP7702952B2 (enExample)
KR (1) KR20220119147A (enExample)
CN (1) CN121873247A (enExample)
BR (1) BR112022012362A2 (enExample)
CL (1) CL2022001706A1 (enExample)
CO (1) CO2022010294A2 (enExample)
DO (2) DOP2022000136A (enExample)
GB (1) GB201919294D0 (enExample)
MX (1) MX2022007957A (enExample)
PE (1) PE20230384A1 (enExample)
WO (1) WO2021130502A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
GB202214979D0 (en) * 2022-10-11 2022-11-23 Eco Animal Health Ltd Binding protein
EP4655324A1 (en) * 2023-01-27 2025-12-03 Vib Vzw Cd163-binding conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119569865B (zh) * 2024-12-20 2025-10-10 西北农林科技大学 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65691B1 (sr) 2015-08-06 2024-07-31 Univ Missouri Svinja i ćelije rezistentne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modifikovane cd163 gene
US11160260B2 (en) * 2018-04-17 2021-11-02 The Curators Of The University Of Missouri Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)

Also Published As

Publication number Publication date
US20230203185A1 (en) 2023-06-29
WO2021130502A1 (en) 2021-07-01
KR20220119147A (ko) 2022-08-26
CA3162664A1 (en) 2021-07-01
JP2023508674A (ja) 2023-03-03
CN115151569A (zh) 2022-10-04
GB201919294D0 (en) 2020-02-05
BR112022012362A2 (pt) 2022-09-06
JP7702952B2 (ja) 2025-07-04
DOP2022000136A (es) 2022-11-30
DOP2025000290A (es) 2026-02-26
CO2022010294A2 (es) 2022-10-31
EP4081542A1 (en) 2022-11-02
PE20230384A1 (es) 2023-03-06
CL2022001706A1 (es) 2023-05-26
CN121873247A (zh) 2026-04-17

Similar Documents

Publication Publication Date Title
MX2022007957A (es) Proteinas de union a o anticuerpos contra cd163.
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
PH12021550662A1 (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
AR109882A1 (es) Anticuerpos monoclonales neutralizantes anti-tl1a
JP2023528235A5 (enExample)
MY200988A (en) CD3 Binding Antibodies
WO2013078455A3 (en) Proteomic identification of antibodies
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
JP2018512138A5 (enExample)
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
IL212949A (en) Anti-4cd human antibody capable of activating CD25 + CD4 + regulatory T cells and using it to prepare a drug for the treatment or prevention of immune disease
PE20120475A1 (es) Anticuerpos especificos para dkk-1
JP2014529610A5 (enExample)
PH12022552520A1 (en) Antibodies binding siglec15 and uses thereof
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
WO2020257789A3 (en) Anti-tim-3 antibodies
MY210018A (en) Monoclonal antibody that binds specifically to gitr
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
ZA202308896B (en) Antibodies binding trop2 and uses thereof
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät
WO2023202672A9 (en) Antibodies targeting sirp-alpha and uses thereof
MX2025000311A (es) Constructos de union a antigeno dll3
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.